Molecular imaging and contrast agent database (MICAD): Evolution and progress

Molecular Imaging and Biology

Volumn 14, Issue 1, 2012, Pages 4-13

  Chopra, Arvind ^a   Shan, Liang ^a   Eckelman, W C ^a   Leung, Kam ^a   Latterner, Martin ^a   Bryant, Stephen H ^a   Menkens, Anne ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Contrast agents; Database; Magnetic resonance imaging (MRI); Molecular imaging probes; Optical imaging (OI); Positron emission tomography (PET); Single photon emission computed tomography (SPECT); Ultrasound imaging; X ray computed tomography (X ray CT)

Indexed keywords

CONTRAST MEDIUM;

ACCESS TO INFORMATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DATA EXTRACTION; EXPERIMENTAL ANIMAL; GOVERNMENT REGULATION; IMAGE ANALYSIS; IN VITRO STUDY; INFORMATION DISSEMINATION; INFORMATION RETRIEVAL; INFORMATION STORAGE; MOLECULAR IMAGING; MOLECULAR IMAGING AND CONTRAST AGENT DATABASE; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONLINE SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REFERENCE DATABASE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; X RAY ANALYSIS;

ANIMALS; CONTRAST MEDIA; DATABASE MANAGEMENT SYSTEMS; DATABASES, FACTUAL; DIAGNOSTIC IMAGING; HUMANS; INTERNET; MOLECULAR IMAGING; MOLECULAR PROBES; USER-COMPUTER INTERFACE;

EID: 84861482093     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0521-3     Document Type: Review

References (27)

1. Cheng KT, Menkens A, Bryant S et al (2007) NIH MICAD initiative and guest author program opportunities. J Nucl Med 48:19N
2. Chopra A, Shan L, Eckelman EC, et al. (2011) Important parameters to consider for the characterization of PET and SPECT imaging probes. Nucl Med Biol [Epub ahead of print].
3. Willmann JK, van Bruggen N, Dinkelborg LM et al (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591-607 (Pubitemid 351927724)
4. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545-580 (Pubitemid 36307540)
5. Piwnica-Worms DR (2004) Introduction to molecular imaging. J Am Coll Radiol 1:2-3
6. Amidon GL (2004) Molecular pharmaceutics: the NIH Roadmap and the FDA pipeline problem. Mol Pharm 1:337
7. Check E (2003) NIH 'roadmap' charts course to tackle big research issues. Nature 425:438
8. Shi ZD, Wu H, Ruddy B et al (2007) Imaging Probe Development Center: a National Institutes of Health core synthesis resource for imaging probes. J Biomed Opt 12:051502
9. Sayers EW, Barrett T, Benson DA et al (2011) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 39:D38-D51
10. Haight AE, Kaste SC, Goloubeva OG et al (2003) Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bonemarrow transplantation. Radiology 226:399-404 (Pubitemid 36313426)
11. Weichert JP, Lee FT Jr, Longino MA et al (1998) Lipid-based bloodpool CT imaging of the liver. Acad Radiol 5(Suppl 1):S16-S19, discussion S28-30
12. Ford NL, Graham KC, Groom AC et al (2006) Time-course characterization of the computed tomography contrast enhancement of an iodinated blood-pool contrast agent in mice using a volumetric flat-panel equipped computed tomography scanner. Invest Radiol 41:384-390 (Pubitemid 44284200)
13. Cheong BY, Muthupillai R (2010) Nephrogenic systemic fibrosis: a concise review for cardiologists. Tex Heart Inst J 37:508-515
14. Cho EC, Glaus C, Chen J et al (2010) Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med 16:561-573
15. Godin B, Driessen WH, Proneth B et al (2010) An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet 69:31-64
16. Louie A (2010) Multimodality imaging probes: design and challenges. Chem Rev 110:3146-3195
17. Hasebroock KM, Serkova NJ (2009) Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 5:403-416
18. Hallouard F, Anton N, Choquet P et al (2010) Iodinated blood pool contrast media for preclinical X-ray imaging applications - a review. Biomaterials 31:6249-6268
19. Kozlowska D, Foran P, MacMahon P et al (2009) Molecular and magnetic resonance imaging: the value of immunoliposomes. Adv Drug Deliv Rev 61:1402-1411
20. Sheth RA, Mahmood U (2010) Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 299:G807-G820
21. Longmire MR, Ogawa M, Hama Y et al (2008) Determination of optimal rhodamine fluorophore for in vivo optical imaging. Bioconjug Chem 19:1735-1742
22. Eckelman WC, Kilbourn MR, Joyal JL et al (2007) Justifying the number of animals for each experiment. Nucl Med Biol 34:229-232 (Pubitemid 46442899)
23. Boerman OC, Rennen H, Oyen WJ et al (2001) Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 31:286-295 (Pubitemid 33027507)
24. Chen JH, Baek HM, Nalcioglu O et al (2008) Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging 27:825-833 (Pubitemid 351508098)
25. Roelofs AJ, Thompson K, Gordon S et al (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s-6230s (Pubitemid 44703794)
26. Mukherjee S, Mani S (2010) Orphan nuclear receptors as targets for drug development. Pharm Res 27:1439-1468
27. Ozawa A, Lindberg I, Roth B et al (2010) Deorphanization of novel peptides and their receptors. AAPS J 12:378-384